MAYNE PHARMA GROUP LIMITED (MYX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MYX - MAYNE PHARMA GROUP LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences

Year End: June

GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences

Debt/EBITDA: -4.14

Index: ASX300 | ALL-ORDS

Mayne Pharma is an Australian pharmaceuticals development and manufacturing company with facilities in Australia and the US. It also provides development and manufacturing services to global clients. It listed in 2007.

LAST PRICE	CHANGE +/-	CHANGE %	VOLUME
$5.81 09 Oct 2025	0.100 OPEN $5.76	1.75% HIGH $5.85	273,630 LOW $5.67

LAST PRICE

CHANGE +/-

CHANGE %

VOLUME

$5.81

09 Oct
2025

0.100

OPEN

$5.76

1.75%

HIGH

$5.85

273,630

LOW

$5.67

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .

FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD

Copyright © 2025 FactSet UK Limited. All rights reserved

Title	2020	2021	2022	2023	2024	2025
EPS Basic	xxx	xxx	xxx	xxx	xxx	-118.6
DPS All	xxx	xxx	xxx	xxx	xxx	0.0
Sales/Revenue	xxx	xxx	xxx	xxx	xxx	408.1 M
Book Value Per Share	xxx	xxx	xxx	xxx	xxx	455.8
Net Operating Cash Flow	xxx	xxx	xxx	xxx	xxx	20.9 M
Net Profit Margin	xxx	xxx	xxx	xxx	xxx	-22.07 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title	2020	2021	2022	2023	2024	2025
Return on Capital Employed	xxx	xxx	xxx	xxx	xxx	-21.85 %
Return on Invested Capital	xxx	xxx	xxx	xxx	xxx	-20.90 %
Return on Assets	xxx	xxx	xxx	xxx	xxx	-8.35 %
Return on Equity	xxx	xxx	xxx	xxx	xxx	-21.85 %
Return on Total Capital	xxx	xxx	xxx	xxx	xxx	-5.24 %
Free Cash Flow ex dividends	xxx	xxx	xxx	xxx	xxx	9.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title	2020	2021	2022	2023	2024	2025
Short-Term Debt	xxx	xxx	xxx	xxx	xxx	39 M
Long Term Debt	xxx	xxx	xxx	xxx	xxx	3 M
Total Debt	xxx	xxx	xxx	xxx	xxx	41 M
Goodwill - Gross	xxx	xxx	xxx	xxx	xxx	-
Cash & Equivalents - Generic	xxx	xxx	xxx	xxx	xxx	103 M
Price To Book Value	xxx	xxx	xxx	xxx	xxx	1.10

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title	2020	2021	2022	2023	2024	2025
Capex	xxx	xxx	xxx	xxx	xxx	27.8 M
Capex % of Sales	xxx	xxx	xxx	xxx	xxx	6.81 %
Cost of Goods Sold	xxx	xxx	xxx	xxx	xxx	222 M
Selling, General & Admin. Exp & Other	xxx	xxx	xxx	xxx	xxx	210 M
Research & Development	xxx	xxx	xxx	xxx	xxx	18 M
Investments - Total	xxx	xxx	xxx	xxx	xxx	0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
EXTRA COVERAGE

EXPERT VIEWS

Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY

Access Stockbroker Research History >

EXTRA COVERAGE

Display All Commentary

No. Of Recommendations

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY
Canaccord Genuity	07/09/2025	1	Buy	$6.10	4.99%	Mayne Pharma's FY25 revenue of $408.1m was up 5% y/y and was ahead of Canaccord Genuity's forecast of $393m. Gross margin of 60% was higher than FY24, and operating cash flow came in at $45.4m. The key takeaway in the broker's view was the result didn't appear to violate MAC (material adverse change) clause, but there's uncertainty due to Cosette's attempt to terminate the acquisition deal. No guidance was provided and focus remains on the outcome of the legal proceeding with Cosette. Next hearing is due to start September 22. Buy. Target unchanged at $6.10.

BROKER

DATE

RATING

RECOMMENDATION

TARGET PRICE

% TO REACH TARGET

COMMENTARY

Canaccord Genuity

07/09/2025

Buy

$6.10

4.99%

Mayne Pharma's FY25 revenue of $408.1m was up 5% y/y and was ahead of Canaccord Genuity's forecast of $393m. Gross margin of 60% was higher than FY24, and operating cash flow came in at $45.4m.

The key takeaway in the broker's view was the result didn't appear to violate MAC (material adverse change) clause, but there's uncertainty due to Cosette's attempt to terminate the acquisition deal.

No guidance was provided and focus remains on the outcome of the legal proceeding with Cosette. Next hearing is due to start September 22.

Buy. Target unchanged at $6.10.

Access Extra Coverage Research History >

MYX STOCK CHART

FNArena News on MYX

1	Next Week At A Glance – 15-19 Sep 2025 Sep 12 2025 - Weekly Reports

2	Australian Broker Call Extra Edition – Sep 08, 2025 Sep 08 2025 - Daily Market Reports

3	Next Week At A Glance – 8-12 Sep 2025 Sep 05 2025 - Weekly Reports

4	In Case You Missed It – BC Extra Upgrades & Downgrades – 01-08-25 Aug 01 2025 - Weekly Reports

5	Australian Broker Call Extra Edition – Jul 30, 2025 Jul 30 2025 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1	Is CSL Starting Its Price Recovery? Sep 30 2025 - Technicals

2	Undervalued ASX Gems In Precision Medicine Sep 23 2025 - Small Caps

3	Earnings Result Leaves CSL Bloodied Aug 21 2025 - Australia

4	Renewed Momentum For CSL Shares Jul 22 2025 - Technicals

5	Treasure Chest: CSL Not A One-Trick Pony Jul 14 2025 - Treasure Chest

6	The Enigma Surrounding Clinuvel Jul 03 2025 - Small Caps

7	Rudi’s View: CSL & NextDC May 08 2025 - Rudi's View

8	Behring Margin Outlook Still Main Game For CSL Feb 13 2025 - Australia

9	Dr Boreham’s Crucible: Arovella Therapeutics Aug 29 2024 - Small Caps

10	ResMed’s Margin Upside Excites Aug 07 2024 - Australia

Get 2 Weeks free trial

Sign Up

Member Login

MAYNE PHARMA GROUP LIMITED (MYX)
Share Price Analysis and Chart